{"id":"NCT02914522","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis","officialTitle":"Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-14","primaryCompletion":"2020-03-31","completion":"2020-03-31","firstPosted":"2016-09-26","resultsPosted":"2021-04-21","lastUpdate":"2021-04-21"},"enrollment":1351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Filgotinib","otherNames":["GS-6034","GLPG0634"]},{"type":"DRUG","name":"PTM filgotinib","otherNames":[]}],"arms":[{"label":"Induction Study (Cohort A): Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Induction Study (Cohort A): Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Induction Study (Cohort A): Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Induction Study (Cohort B): Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Induction Study (Cohort B): Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Induction Study (Cohort B): Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg","type":"EXPERIMENTAL"},{"label":"Maintenance Study: Placebo From Induction Filgotinib 200 mg","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg","type":"EXPERIMENTAL"},{"label":"Maintenance Study: Placebo From Induction Filgotinib 100 mg","type":"PLACEBO_COMPARATOR"},{"label":"Maintenance Study: Placebo From Induction Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced.\n\nParticipants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).","primaryOutcome":{"measure":"Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10","timeFrame":"Week 10","effectByArm":[{"arm":"Induction Study (Cohort A): Filgotinib 200 mg","deltaMin":26.1,"sd":null},{"arm":"Induction Study (Cohort A): Filgotinib 100 mg","deltaMin":19.1,"sd":null},{"arm":"Induction Study (Cohort A): Placebo","deltaMin":15.3,"sd":null},{"arm":"Induction Study (Cohort B): Filgotinib 200 mg","deltaMin":11.5,"sd":null},{"arm":"Induction Study (Cohort B): Filgotinib 100 mg","deltaMin":9.5,"sd":null},{"arm":"Induction Study (Cohort B): Placebo","deltaMin":4.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0157"},{"comp":"OG001 vs OG002","p":"0.3379"},{"comp":"OG003 vs OG005","p":"0.0103"},{"comp":"OG004 vs OG005","p":"0.0645"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":343,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","France","Georgia","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["39656830","39452892","38019901","37718932","37540206","36946138","36928705","36756874","36006011","34090625"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":245},"commonTop":["Colitis ulcerative","Nasopharyngitis","Headache","Anaemia","Abdominal pain"]}}